PureTech Health plc (LON:PRTC - Get Free Report) rose 14.6% during mid-day trading on Saturday . The company traded as high as GBX 118 ($1.57) and last traded at GBX 118 ($1.57). Approximately 1,623,564 shares traded hands during trading, an increase of 54% from the average daily volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.37).
PureTech Health Stock Performance
The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The business's 50-day moving average is GBX 133.46 and its 200-day moving average is GBX 147.37. The company has a market capitalization of £370.67 million, a PE ratio of -5.06 and a beta of 1.02.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Featured Articles
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
